Bringing a molecular signature to market is a time-consuming and expensive process. This is due in large part to discovery platforms that are too costly and complicated for clinical use and clinical platforms that are poorly suited for high-complexity validation studies. DxTerity has developed a DNA-testing platform that bridges this gap.
By streamlining the process for transitioning a signature from discovery through validation and to point-of-care use, DxTerity fills a critical need in the market, ultimately making the signature validation process possible within a one-year timeframe.
The NEAT™-platform boarding methodology allows rapid development on the DxTerity Microarray System with direct portability to DxTerity’s point-of-care–capable instruments while delivering identical, highly quantitative test results.
Now molecular diagnostic companies have a clearly defined path to move their genomic signature through validation and port directly to an automated platform, freeing them to focus on FDA approval and clinical utility of their signature. Ultimately, DxTerity customers will have open-platform access to deliver directly to thousands of points of care.
